RSV Hospitalization in Down Syndrome in the Canadian Registry of Synagis (CARESS) Following Prophylaxis (2006–2011)

Paediatrics in Vienna

“…Prophylaxis with palivizumab reduces disease severity in high-risk infants, but is poorly effective. In a prospective study, enrolling over 10 000 Canadian infants who received at least one palivizumab dose during the 2006-2011 RSV seasons, MITCHELL et al [100] reported a subsequent hospital admission rate of 1.6% for bronchiolitis. Most hospital admissions for RSV bronchiolitis are in infants ineligible for prophylaxis.…”